
ProbeChem®
*Expedite Your Scientific Research*

WWW.PROBECHEM.COM

# Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

| | | |
|---|---|---|
| **Product Name** | : | Pilaralisib |
| **Cat. No.** | : | PC-28709 |
| **CAS No.** | : | 934526-89-3 |
| **Molecular Formula** | : | $C_{25}H_{25}ClN_6O_4S$ |
| **Molecular Weight** | : | 541.02 |
| **Target** | : | PI3K |
| **Solubility** | : | 10 mM in DMSO |



## Biological Activity

Pilaralisib (XL147, SAR245408) is a potent and highly selective, orally active **class I PI3Ks** inhibitor with IC50s of 39 nM, 383 nM, 23 nM and 36 nM for **PI3Kα**, **PI3Kβ**, **PI3Kγ**, and **PI3Kδ** respectively.
Pilaralisib (XL147, SAR245408) shows broad kinase selectivity profiling of >130 protein kinases.
Pilaralisib (XL147, SAR245408) inhibits the formation of PIP3 in the membrane, and inhibits phosphorylation of AKT, p70S6K, and S6 in multiple tumor cell lines with diverse genetic alterations affecting the PI3K pathway in cellular assays.
Pilaralisib (XL147, SAR245408) inhibits proliferation with a wide range of potencie in a panel of tumor cell lines.
Pilaralisib (XL147, SAR245408) induces dose-dependent inhibition of phosphorylation of AKT, p70S6K, and S6 with a duration of action of at least 24 hours in mouse xenograft models, causes significant tumor growth inhibition in multiple human xenograft models in nude mice.

## References


Foster P, et al. ***Mol Cancer Ther.*** 2015 Apr;14(4):931-40.

Chakrabarty A, et al. ***Proc Natl Acad Sci U S A***. 2012 Feb 21;109(8):2718-23.



**Caution: Product has not been fully validated for medical applications. Lab Use Only!**



E-mail: tech@probechem.com